Multicenter randomized phase 2 trial of first-line mFOLFIRINOX versus gemcitabine plus nab-paclitaxel for mPDAC

The randomized phase 2 PASS-01 trial in Canada and the United States compared modified FOLFIRINOX versus gemcitabin plus nab-paclitaxel (GnP) among patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Progression-free survival was similar between mFOLFIRINOX and GnP (median, 4.0 versus 5.3 months; HR 1.37; p=0.06); however, overall survival was better with GnP (median, 8.5 months versus 9.7 months; HR 1.57; p=0.017).